Eli Lilly Halves Investment in German Plant Amid Healthcare Law Concerns
Eli Lilly is slashing its €2.3 billion investment in a German manufacturing plant by half due to proposed healthcare cost-cutting legislation. CEO Dave Ricks criticized the reforms, warning Germany could fall behind other European markets. The reduced investment will impact factory output and job creation.







